Cross-border tumor boards of cancer specialists from different European countries meeting virtually to review the management of individual patients with complex rare gynecological cancers from across Europe resulted in new treatment recommendations and increased access to clinical trials, according to results from a six-year study that will be presented at the ESMO Gynaecological Cancers Congress 2024.
Blueprint ups Ayvakit guidance; Aurinia to advance autoimmune disease asset
Plus, news about Novo Holdings, Oxford Nanopore, Ionis, Valneva, LimmaTech and Bayer: Blueprint pulls in $114.1 million for Ayvakit: The company Sign up to read